Articles with public access mandates - Professor Michael S. HofmanLearn more
Not available anywhere: 36
Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu …
SP Thang, J Violet, S Sandhu, A Iravani, T Akhurst, G Kong, AR Kumar, ...
European urology oncology 2 (6), 670-676, 2019
Mandates: National Health and Medical Research Council, Australia, Ministry of Health …
Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial
IW Sim, GL Borromeo, C Tsao, R Hardiman, MS Hofman, ...
Journal of Clinical Oncology 38 (26), 2971-2980, 2020
Mandates: National Health and Medical Research Council, Australia
Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol
A Iravani, B Solomon, DA Pattison, P Jackson, A Ravi Kumar, G Kong, ...
Thyroid 29 (11), 1634-1645, 2019
Mandates: National Health and Medical Research Council, Australia
Estimating lung ventilation directly from 4D CT Hounsfield unit values
J Kipritidis, MS Hofman, S Siva, J Callahan, PY Le Roux, HC Woodruff, ...
Medical physics 43 (1), 33-43, 2016
Mandates: National Health and Medical Research Council, Australia
[68Ga] Ga-PSMA versus [18F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature
L Evangelista, T Maurer, H van der Poel, F Alongi, J Kunikowska, ...
European Urology Oncology 5 (3), 273-282, 2022
Mandates: US Department of Defense, National Health and Medical Research Council …
Ventilation/perfusion positron emission tomography—based assessment of radiation injury to lung
S Siva, N Hardcastle, T Kron, M Bressel, J Callahan, MP MacManus, ...
International Journal of Radiation Oncology* Biology* Physics 93 (2), 408-417, 2015
Mandates: National Health and Medical Research Council, Australia
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide …
G Kong, J Callahan, MS Hofman, DA Pattison, T Akhurst, M Michael, P Eu, ...
European journal of nuclear medicine and molecular imaging 44, 476-489, 2017
Mandates: National Health and Medical Research Council, Australia
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
A Iravani, MM Osman, AM Weppler, R Wallace, A Galligan, A Lasocki, ...
European journal of nuclear medicine and molecular imaging 47, 2776-2786, 2020
Mandates: National Health and Medical Research Council, Australia
Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy
N Dhiantravan, J Violet, R Eapen, O Alghazo, M Scalzo, P Jackson, ...
European urology focus 7 (2), 234-237, 2021
Mandates: Medical Research Future Fund, Australia
Using PSMA imaging for prognostication in localized and advanced prostate cancer
MJ Roberts, T Maurer, M Perera, M Eiber, TA Hope, P Ost, S Siva, ...
Nature Reviews Urology 20 (1), 23-47, 2023
Mandates: German Research Foundation
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
S Siva, C Udovicich, B Tran, H Zargar, DG Murphy, MS Hofman
Nature Reviews Urology 17 (2), 107-118, 2020
Mandates: National Health and Medical Research Council, Australia
Accuracy and utility of deformable image registration in 68Ga 4D PET/CT assessment of pulmonary perfusion changes during and after lung radiation therapy
N Hardcastle, MS Hofman, RJ Hicks, J Callahan, T Kron, MP MacManus, ...
International Journal of Radiation Oncology* Biology* Physics 93 (1), 196-204, 2015
Mandates: National Health and Medical Research Council, Australia
Radiation dosimetry in 177Lu-PSMA-617 therapy
P Jackson, M Hofman, L McIntosh, JP Buteau, AR Kumar
Seminars in Nuclear Medicine 52 (2), 243-254, 2022
Mandates: US Department of Defense
Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature
G Ploussard, N Fossati, T Wiegel, A D'Amico, MS Hofman, S Gillessen, ...
European urology oncology 4 (2), 150-169, 2021
Mandates: US Department of Defense, Medical Research Future Fund, Australia
ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration …
L Emmett, S Subramaniam, AM Joshua, M Crumbaker, A Martin, ...
BJU international 128 (5), 642-651, 2021
Mandates: National Health and Medical Research Council, Australia, Medical Research …
Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer
L Bukavina, AN Luckenbaugh, MS Hofman, T Hope, SC Kamran, ...
European Urology 83 (6), 521-533, 2023
Mandates: US Department of Defense, National Health and Medical Research Council …
Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary …
A Farolfi, B Hadaschik, FC Hamdy, K Herrmann, MS Hofman, DG Murphy, ...
European urology oncology 4 (5), 714-730, 2021
Mandates: US Department of Defense, Medical Research Future Fund, Australia
Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option
N Mayor, NJ Sathianathen, J Buteau, S Koschel, M Antón Juanilla, ...
BJU international 126 (5), 525-535, 2020
Mandates: US Department of Defense
Use of prostate‐specific membrane antigen positron‐emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer
A Anton, O Kamel Hasan, Z Ballok, P Bowden, AJ Costello, L Harewood, ...
BJU international 126 (4), 433-435, 2020
Mandates: US Department of Defense, Medical Research Future Fund, Australia
Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series
A Iravani, C Mitchell, T Akhurst, S Sandhu, MS Hofman, RJ Hicks
Clinical Genitourinary Cancer 19 (4), e200-e205, 2021
Mandates: National Health and Medical Research Council, Australia
Publication and funding information is determined automatically by a computer program